Intrahepatic Cholangiocarcinoma Market to grow significantly by 2032 | Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, and others

(Delhi, India) To strategically aid companies developing drugs for Intrahepatic Cholangiocarcinoma, DelveInsight launched the report “Intrahepatic Cholangiocarcinoma Market” This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Intrahepatic Cholangiocarcinoma Market.

Download a free sample copy of “Intrahepatic Cholangiocarcinoma Market Report”

Key Highlights from the Intrahepatic Cholangiocarcinoma Market Report

• As per DelveInsight analysts, in Japan Intrahepatic Cholangiocarcinoma is more common in the people of age group 80 and above. As per the estimates, the total incident cases of Intrahepatic Cholangiocarcinoma in this age group in Japan were ~7,400 in 2022.
• In 2022, the Intrahepatic Cholangiocarcinoma Diagnosed Incident Cases in Japan were found to be ~16,700 among which total Intrahepatic Cholangiocarcinoma cases were ~8,900.
• The Intrahepatic Cholangiocarcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intrahepatic Cholangiocarcinoma pipeline products will significantly revolutionize the Intrahepatic Cholangiocarcinoma market dynamics.
• The leading companies working in the Intrahepatic Cholangiocarcinoma Market include Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Glaxosmithkline, Merck/Glaxosmithkline, Eisai, Taiho Pharmaceutical/Servier, Bayer, Sorrento Therapeutics/Yuhan Corporation, Hutchison Medipharma, Jiangsu Hengrui Medicine, Astrazeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array Biopharmas, and others.
• Promising Intrahepatic Cholangiocarcinoma Pipeline Therapies in the various stages of development include Cisplatin-gemcitabine, HMPL-453, ICP-192, derazantinib, VG161, Nivolumab Injection [Opdivo], and others.

Intrahepatic Cholangiocarcinoma Country-based Treatment Analysis

The Intrahepatic Cholangiocarcinoma treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Intrahepatic Cholangiocarcinoma therapies that have the potential treatment paradigms and improve patient outcomes.

Intrahepatic cholangiocarcinoma (iCCA) is a malignant intrahepatic epithelial neoplasm with biliary differentiation, arising in the liver periphery / proximal to the left and right hepatic ducts, Intrahepatic cholangiocarcinoma (iCCA) is a primary carcinoma of the liver with increasing significance and major pathogenic, clinical and therapeutic challenges. Classically, it arises from malignant transformation of cholangiocytes bordering small portal bile duct (BD) to second-order segmental large BDs.

Download the report to understand which factors are driving Intrahepatic Cholangiocarcinoma epidemiology trends @ Intrahepatic Cholangiocarcinoma Epidemiology Forecast

Intrahepatic Cholangiocarcinoma Epidemiology Insights:-

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Intrahepatic Cholangiocarcinoma. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the Intrahepatic Cholangiocarcinoma market dynamics. Further, the Intrahepatic Cholangiocarcinoma epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools. The epidemiology in report is segmented as:

• Intrahepatic Cholangiocarcinoma Diagnosed Incident Cases
• Intrahepatic Cholangiocarcinoma Age-specific Cases
• Intrahepatic Cholangiocarcinoma Mutation-specific Cases
• Total Intrahepatic Cholangiocarcinoma Diagnosed Incident Cases
• Intrahepatic Cholangiocarcinoma Stage-specific Cases
• Total Intrahepatic Cholangiocarcinoma Treated Cases

“As per DelveInsight analysts, the total Intrahepatic Cholangiocarcinoma incident population in the US was estimated to be ~5,000 in 2022”

Intrahepatic Cholangiocarcinoma Companies and Therapies

• Cisplatin-gemcitabine: Sirtex Medical
• HMPL-453: Hutchmed
• ICP-192: Beijing InnoCare Pharma Tech Co., Ltd.
• Derazantinib: Basilea Pharmaceuticals
• VG161: Virogin Biotech Canada Ltd

Intrahepatic Cholangiocarcinoma Drugs Uptake

LYTGOBI (futibatinib): LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. In September 2022, the US FDA granted accelerated approval to Taiho Oncology’s LYTGOBI for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. LYTGOBI previously received breakthrough, orphan drug and priority review designations from the FDA.

Locoregional therapy: The role of locoregional therapies, such as transarterial chemoembolization (TACE) and transarterial radioembolization (TARE), is being investigated for BTC patients. In retrospective studies, TACE with cisplatin has improved survival in unresectable iCCA.

Immunotherapy: Immunotherapy activates the patient’s immune system. The body’s natural defenses against cancer are boosted, directed, or restored using substances produced by the body or in a lab. Immunotherapy includes treatments using immune checkpoint inhibitors.

Targeted therapy: Patients with bile duct cancer that has migrated to other regions of the body or is locally progressed and cannot be removed by surgery are being researched for the following targeted therapies: ivosidenib, pemigatinib, and infigratinib.

To know more about Intrahepatic Cholangiocarcinoma Companies working in the treatment market, visit @ Intrahepatic Cholangiocarcinoma Clinical Trials and Therapeutic Assessment

Intrahepatic Cholangiocarcinoma Market Forecast

The Intrahepatic Cholangiocarcinoma market has witnessed significant growth in recent years, driven by a surge in the incidence of this rare cancer and a growing understanding of its molecular characteristics. According to various market research reports, the global Intrahepatic Cholangiocarcinoma market is anticipated to experience a steady increase in valuation, propelled by advancements in diagnostic technologies, therapeutic approaches, and a rising awareness of the disease.

Discover more about therapies set to grab major Intrahepatic Cholangiocarcinoma Market Share @ Intrahepatic Cholangiocarcinoma Treatment Market

Scope of the Intrahepatic Cholangiocarcinoma Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Intrahepatic Cholangiocarcinoma Companies- Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Glaxosmithkline, Merck/Glaxosmithkline, Eisai, Taiho Pharmaceutical/Servier, Bayer, Sorrento Therapeutics/Yuhan Corporation, Hutchison Medipharma, Jiangsu Hengrui Medicine, Astrazeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array Biopharmas, and others.
• Intrahepatic Cholangiocarcinoma Pipeline Therapies- Cisplatin-gemcitabine, HMPL-453, ICP-192, derazantinib, VG161, Nivolumab Injection [Opdivo], and others.

Note: 

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Intrahepatic Cholangiocarcinoma Market Landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the Intrahepatic Cholangiocarcinoma market, including the competitive environment, key companies developing drugs for Intrahepatic Cholangiocarcinoma, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Intrahepatic Cholangiocarcinoma market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Intrahepatic Cholangiocarcinoma. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan Roadmap to Success: Through this report, the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Intrahepatic Cholangiocarcinoma Market with clarity and purpose.

Related Reports

Intrahepatic Cholangiocarcinoma Epidemiology Forecast 2032

DelveInsight's Intrahepatic Cholangiocarcinoma Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.

Intrahepatic Cholangiocarcinoma Pipeline Insight 2023

Intrahepatic Cholangiocarcinoma Pipeline Insights 2023 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European Bio Similar landscape. Download Pharma Go-to-Market Case Study!

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/